Table 3 Common adverse events reported during either 12-week treatment period
From: Cannabinoid treatment for autism: a proof-of-concept randomized trial
|
Whole-plant extract CBD 5.5 mg/kg/d; n = 95 (%) |
Pure cannabinoids CBD 5.5 mg/kg/d; n = 93 (%) |
Placebo n = 94 (%) | P value (placebo vs cannabinoids) | |
|---|---|---|---|---|
| Somnolence | 27 | 24 | 7.5 | < 0.001 |
| Mild | 20 | 18.5 | 7.5 | |
| Moderate | 7 | 5.5 | 0 | |
| Severe | 0 | 0 | 0 | |
| Decreased appetite | 24 | 22 | 15 | 0.157 |
| Mild | 21 | 16.5 | 13 | |
| Moderate | 3 | 5.5 | 2 | |
| Severe | 0 | 0 | 0 | |
| Weight loss | 12 | 13 | 4 | 0.053 |
| Mild | 9 | 12 | 3 | |
| Moderate | 3 | 1 | 1 | |
| Severe | 0 | 0 | 0 | |
| Tiredness | 25 | 34 | 19 | 0.077 |
| Mild | 21 | 28.5 | 18 | |
| Moderate | 4 | 5.5 | 1 | |
| Severe | 0 | 0 | 0 | |
| Euphoria | 20 | 19 | 13 | 0.201 |
| Mild | 15 | 16 | 12 | |
| Moderate | 5 | 3 | 1 | |
| Severe | 0 | 0 | 0 | |
| Anxiety | 20 | 27 | 14 | 0.084 |
| Mild | 17 | 25 | 11 | |
| Moderate | 3 | 2 | 3 |